Lin Shiuan-Chen, Ma Chun, Chang Kao-Jung, Cheong Han-Ping, Lee Ming-Cheng, Lan Yuan-Tzu, Wang Chien-Ying, Chiou Shih-Hwa, Huo Teh-Ia, Hsu Tsui-Kang, Tsai Ping-Hsing, Yang Yi-Ping
School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Biomedicines. 2022 Sep 2;10(9):2169. doi: 10.3390/biomedicines10092169.
The with-no-lysine (WNK) kinase family, comprising four serine-threonine protein kinases (WNK1-4), were first linked to hypertension due to their mutations in association with pseudohypoaldosteronism type II (PHAII). WNK kinases regulate crucial blood pressure regulators, SPAK/OSR1, to mediate the post-translational modifications (PTMs) of their downstream ion channel substrates, such as sodium chloride co-transporter (NCC), epithelial sodium chloride (ENaC), renal outer medullary potassium channel (ROMK), and Na/K/2Cl co-transporters (NKCCs). In this review, we summarize the molecular pathways dysregulating the WNKs and their downstream target renal ion transporters. We summarize each of the genetic variants of WNK kinases and the small molecule inhibitors that have been discovered to regulate blood pressure via WNK-triggered PTM cascades.
无赖氨酸(WNK)激酶家族由四种丝氨酸 - 苏氨酸蛋白激酶(WNK1 - 4)组成,最初因其与II型假性醛固酮增多症(PHAII)相关的突变而与高血压联系在一起。WNK激酶调节关键的血压调节因子SPAK/OSR1,以介导其下游离子通道底物的翻译后修饰(PTM),如氯化钠共转运体(NCC)、上皮氯化钠(ENaC)、肾外髓质钾通道(ROMK)和钠/钾/2氯共转运体(NKCCs)。在本综述中,我们总结了WNK及其下游靶肾离子转运体失调的分子途径。我们总结了WNK激酶的每种基因变体以及已发现通过WNK触发的PTM级联反应来调节血压的小分子抑制剂。